Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Kathryn Lurain
Cancer Immunotherapy Trials Network
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States
- Ucsf Medical Center-Parnassus
San Francisco, California, United States
- Zuckerberg San Francisco General Hospital
San Francisco, California, United States
- Yale University
New Haven, Connecticut, United States
- Louisiana State University Health Science Center
New Orleans, Louisiana, United States
- Johns Hopkins University/sidney Kimmel Cancer Center
Baltimore, Maryland, United States
- University of Maryland/greenebaum Cancer Center
Baltimore, Maryland, United States
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
- Roswell Park Cancer Institute
Buffalo, New York, United States
- Laura and Isaac Perlmutter Cancer Center at Nyu Langone
New York, New York, United States
- Mount Sinai Hospital
New York, New York, United States
- Fhcc South Lake Union
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 4 Apr 2016
- Primary completion
- 4 Oct 2023
- Completion
- 25 Mar 2024
- Last update posted
- 9 Aug 2024
- Registered enrollment
- 58
- Registry id
- NCT02595866
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.